Patient-preferred Outcomes,
Proven by Data1,2
Aquablation therapy is the only image-guided, robotic-assisted, heat-free waterjet for the treatment of BPH.
Harness the power of robotic-assisted waterjet technology with Aquablation therapy.
Discover the BPH treatment that meets your goals – and your patient’s
10+ Years of Aquablation Therapy
Early Clinical Validation
Contemporary Practice
Proven Outcomes1-2
Analysis of 18 Publications (Studied Internationally)
Aquablation Therapy: Delivers Measurable Value
Clinical2
Deliver Proven Outcomes
4 key markers:
Operational3
Maximize Throughput
1HR
Data supports <1 hour operative time
Economic4
Dedicated Codes
Category I code effective January, 2026
Attending AUA?
Thought Leader Presentations at
PROCEPT BioRobotics Booth #1431
Saturday, April 26 | Live at Booth #1431
11:45 AM PST
How Aquablation Therapy Continues to Transform My BPH Practice
Dr. Lewis Kriteman – Georgia Urology
12:15 PM PST
Data-Driven Decisions: The Evidence Behind Aquablation Therapy
Dr. Kevin Zorn – BPH Canada
Sunday, April 27 | Live at Booth #1431
11:45 AM PST
Building a High-Impact BPH Service Line: The Role of Aquablation in Modern Urology
Dr. Ravi Munver – Hackensack Meridian Health
12:15 PM PST
Optimizing the BPH Care Pathway: Where Aquablation Therapy Fits in Our Care Algorithm
Dr. Shawn Marhamati – Potomac Urology
Monday, April 28 | Live at Booth #1431
11:45 AM PST
Earlier Intervention for BPH? How Aquablation Therapy Outcomes Reshaped My Thinking
Dr. Christopher Kelly – NYU Langone
Aquablation Therapy Hands-on Workshop with the New HYDROS Robotic System
Saturday, April 26 & Sunday, April 27 | 10:00 AM – 4:00 PM PST
Register for this one-hour small-group session to experience Aquablation therapy and the new HYDROS Robotic System.
Workshop Includes:
- ✔ Introduction to PROCEPT and Aquablation therapy
- ✔ Hands-on learning with an experienced Aquablation therapy surgeon
Evening Event
Saturday, April 26 | 4:30 – 6:30 PM PST
1923 Prohibition inside The Venetian Resort
Join colleagues and PROCEPT BioRobotics executives to learn and share more about the latest in Aquablation therapy, including:
- ✔ New clinical data
- ✔ Trends in BPH patient care pathways
- ✔ Platform advancements with the new HYDROS Robotic System
*Non-CME event
Resident Workshop
Monday, April 27 | 10:00 AM – 4:00 PM PST
Register for a single session, or multiple sessions led by Aquablation therapy thought leaders.
Session 1: 10:00 – 12:00 PST
Introduction to Aquablation Therapy
Dr. Christopher Kelly – NYU Langone
Session 2: 12:15 – 2:15 PST
Why is Aquablation Therapy Unique in the Landscape of BPH
Dr. Ravi Munver – Hackensack Meridian
Session 3: 2:30 – 4:00 PST
Optimizing the Patient Pathway: The Importance of the APP
Alex Hughes, NP – Austin Urology Institute
Not attending AUA? Speak with a local representative.
- Bouhadana D et al. Patient Perspectives on BPH Surgery: Sexual Health Focus; Summary of 18 publications of unique cohorts of data, Data and methodology on file.
- Clinical Data Summary Methodology: Studies with distinct patient cohorts evaluating Aquablation therapy were included, abstracts and unpublished data were excluded. Studies with fewer than 30 patients were excluded. Data was pulled from 18 Aquablation therapy publications up to January 2025. Listed below. Outcomes of interest were aggregated together, and subsequently weighted based on the studies sample size. Not all publications included all outcomes of interest, and thus were excluded from each respective analysis. India, 20-118, n=47, Desai et al. 2. WATER, 30-80ml, n=116, Gilling et al. 3. WATER II, 80-150ml, n=101, Bhojani et al. 4. OPEN WATER, 20-148ml, n=178, Bach et al. 5. FRANCAIS WATER, 30-80ml, n=30, Misrai et al. 6. Very Large prostates, 151-362ml, n=36, Helfand et al. 7. Jacksonville, 27-223ml, n=55, Kasraeian et al. 8. Lebanon, 13-148ml, n=59, Labban et al. 9. Stanford AUR and CUR, 29-250ml, n=113, Burton et al. 10. Montreal ASC, 41-270ml, n=60, Zorn et al. 11. Mount Sinai, 38-330ml, n=330, Omidele et al. 12. Hamburg, 20-154ml, n=118, Bach et al. 13. Japan PMS, 33-242ml, n=103, Hinata et al. 14. Madrid Aquablation vs HoLEP, 72±35ml, n=75, Quintas et al. 15.Israel, 31-138, n=50, Shvero et al. 16. Italy, 43-81, n=109, Amparore et al. 17. Focal Bladder Neck Cautery, 20-263ml, n=2,089, Elterman et al. 18. HoLEP vs Aquablation Hematuria Risk, 56±25ml, n=167, Gloger et al. .
- Nguyen DD, et al. Operative time comparison of aquablation, greenlight PVP, ThuLEP, GreenLEP, and HoLEP. World J Urol. 2020 Dec;38(12):3227-3233. doi: 10.1007/s00345-020-03137-8. Epub 2020 Mar 2.
- Rates are based on CMS Final Rule Making, CMS-1809-FC, Addenda Files (Released November 2024)..